Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
1,435 total articles
H.C. Wainwright raised its price target on Hecla Mining to $36.50 from $16.50 and kept a Buy rating after the miner reported stronger production across silver, gold, lead and zinc. The firm pointed to robust silver market demand and operational improvements, while market metrics show the stock trading at elevated multiples.
H.C. Wainwright has kept a Buy rating and a $16.00 price target on Aclaris Therapeutics (ACRS) after the company reported encouraging preclinical outcomes for ATI-2138 in a severe alopecia areata mouse model. The study, conducted by Dr. Angela Christiano at Columbia University, showed rapid and near-complete hair regrowth that outperformed Pfizer’s…
H.C. Wainwright increased its price target on Intellia Therapeutics to $25.00 from $15.00 and kept a Buy rating after the clinical hold on the MAGNITUDE-2 trial was lifted. Regulators allowed the Phase 3 study for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) to resume under amended safeguards and an increased target enrollmen…
H.C. Wainwright has maintained a Buy rating and a $185.00 price target on Belite Bio (NASDAQ: BLTE) following the company’s announcement that the Phase 2/3 portion of the DRAGON II trial has completed enrollment of 60 adolescent subjects. The stock trades near its 52-week high after a strong year. Several other brokerages have initiated or reiterat…
Wedbush has reaffirmed an Outperform rating and a $350 price target on Apple ahead of the company’s fiscal first-quarter 2026 earnings report, arguing that recent holiday results and strategic initiatives could outpace current market expectations. The stock trades above InvestingPro’s Fair Value, and several other brokerages have issued divergent p…
H.C. Wainwright has reaffirmed a Buy rating and a $24.00 price target on Inventiva SA (NASDAQ: IVA) following a poster presentation at the Keystone Obesity Conference. The investment firm highlighted a unimolecular quintuple agonist described by researchers from Helmholtz Munich as supportive of Inventiva’s therapeutic approach combining GLP-1R and…
Canaccord Genuity has reiterated a Buy rating on Stride Inc. (LRN) and kept a $125.00 price target following the company’s fiscal second-quarter results. The target implies roughly 73% upside versus the current share price of $72.43. Stride delivered revenue and enrollment broadly in line with expectations while reporting profitability above consen…
UBS downgraded Nucor from Buy to Neutral while increasing its price target to $183 from $168. The decision reflects concerns that lower-cost steel imports from Southeast Asia and Brazil became economically viable in mid-October and that additional supply could hit U.S. markets starting in February. The move comes after Nucor outperformed peers sinc…
Barclays has begun coverage of Vertex Pharmaceuticals (NASDAQ: VRTX) with an Overweight rating and a $606 price target, highlighting the companys renal franchise, expected trial readouts in 2026, and potential revenue acceleration for the new acute pain therapy Journavx. Multiple other brokerages have recently raised ratings and price targets for …
UBS raised its target on Seagate Technology to $385 from $335 while retaining a Neutral rating, citing strong execution, expanding gross margins and progress on HAMR technology. The firm also increased EPS forecasts for fiscal 2026-2028 but warned that the stock may be pricing in a prolonged uptrend. Seagate recently posted better-than-expected fis…
Barclays initiated coverage of PTC Therapeutics (NASDAQ: PTCT) with an Overweight rating and a $119 price target, citing the commercial opportunity for the company’s phenylketonuria therapy Sephience and potential upside from Huntington’s disease programs. The target implies meaningful upside from the stock's recent trading level, and Barclays note…
BTIG reduced its price target for Roblox Corp. to $141 from $174 while maintaining a Buy rating ahead of the company’s fourth-quarter results due on February 5. The firm modestly raised bookings estimates for late-2025 and 2026, pointing to a split between weaker concurrent-user metrics and relatively stronger payer and monetization signals. Other …
Barclays initiated coverage of BridgeBio Pharma (BBIO) with an Overweight rating and an $80.00 price target, noting the company’s diversified late-stage portfolio and potential to scale. The move follows strong Attruby sales and preliminary revenue figures for 2025 and coincides with BridgeBio’s $550 million convertible note offering due 2033.
BofA Securities cut Plains All American (PAA) from Neutral to Underperform and kept a $19.00 price target, pointing to constrained Permian Basin production growth, a flat EBITDA forecast through the 2030s, and reduced upside from a lower FERC PPI adder. The bank also downgraded Plains GP Holdings on similar grounds.
Barclays has opened coverage on Bloom Energy (NYSE: BE) with an Equalweight rating and a $153 price objective. The bank cites the company’s rapid site commissioning, falling costs and average selling prices, and recent contract validations as demand drivers for its solid-oxide fuel cell technology, while warning that current market valuation alread…
BofA Securities upgraded Microchip Technology from Neutral to Buy and increased its price target to $95 from $78, citing improving recovery momentum and clearer visibility into demand. The firm boosted its CY26 and CY27 EPS estimates, highlighted the company’s significant industrial and aerospace exposure, and pointed to data-center-facing products…
BofA Securities has initiated coverage of Celestica (NYSE: CLS) with a Buy rating and a $400 price target, highlighting the company’s position in white-box switching and custom ASIC accelerated servers. The firm expects fiscal 2027 to be a standout year as new programs ramp, and bases its valuation on a 32x multiple of calendar 2027 estimated EPS o…
BofA Securities downgraded Plains GP Holdings, L.P. (PAGP) from Neutral to Underperform while keeping a $19.00 price target, pointing to concerns about the long-term trajectory of Permian Basin oil production and regulatory changes that reduce inflation-linked upside. The note also outlines infrastructure and capital-spend scenarios for Plains All …
BofA Securities upgraded Texas Instruments from Underperform to Neutral and raised its price target to $235 from $185 after the company reported in-line fourth-quarter results and provided a first-quarter revenue outlook that exceeded expectations. The bank cited improving backlog and order trends, robust data center demand, and potential for susta…
Morgan Stanley increased its price target on RTX Corp. to $235 from $215 and kept an Overweight rating, pointing to the company’s positioning for continued revenue expansion, margin improvement and potential re-rating by the market. The upgrade follows a robust fourth-quarter performance and a string of price-target adjustments by other brokers, al…
Baird raised its price objective for Texas Instruments to $225 from $195 while maintaining an Outperform rating, pointing to an above-seasonal, unit-driven first-quarter outlook and the company’s exposure to direct customers as reasons it could benefit from an early cycle recovery. Other firms have issued differing updates following Texas Instrumen…
UBS raised its price target on Texas Instruments (TXN) to $260 from $245 and kept a Buy rating, citing stronger revenue trends, improved bookings and constructive backlog commentary. UBS also designated TXN a Top Pick for 2026 and flagged rising free cash flow potential. The stock is trading near $196.63, while other analysts such as Mizuho have ad…
UBS increased its price target for Boeing to $285 from $275 while maintaining a Buy rating, pointing to improving free cash flow and management's emphasis on quality and stability as production ramps. Boeing reported a robust fourth quarter with earnings and revenue that beat expectations, prompting several other analysts to raise their targets.
UBS raised its price objective on RTX to $208 from $199 while retaining a Neutral recommendation after the company reported strong fourth-quarter results. The investment bank pointed to better-than-expected free cash flow in 2025 and 2026 guidance, margin progress across RTX’s businesses and improvements in core cash generation despite higher capit…
UBS increased its 12-month price target on UPS to $125 from $116 while retaining a Buy recommendation, even as it reduced its Q1 earnings-per-share estimate because of near-term margin pressures. UBS and other analysts expect margin headwinds to ease through 2026, with a notable improvement anticipated in the domestic package business in the second…
